Scientific programme | Toulouse Onco Week 2025 - TOW 2025

1. Programme
2. Scientific programme
Scientific programme
Detailed scientific program
LEgend
- Keynotes & plenaries
- Cofee breaks & social events
- Companies technologies
- ISInvited speakers
- SCSelected communications
- person_pin Chairs
- interpreter_mode Presenting author

14:00 - 15:00 |Forecasting pancreatic carcinogenesis

Elana FERTIG - Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, USA

15:00 - 18:30 |Session 1: Artificial Intelligence & Cancer

Elisabeth MOYAL

Vera PANCALDI - INSERM U1037 Centre de Recherche en Cancérologie de Toulouse, France

IS Cancer data infrastructures for computational analysis interpreter_mode Alfonso VALENCIA - BSC-CNS, Spain
SC Cellohood: Discovery of immunological cellular neighborhoods from protein markers in spatial tumor data interpreter_mode Marcin MOZEJKO - University of Warsaw, Poland visibility
IS Using AI to Enhance Care of Glioblastoma Patients interpreter_mode Ahmad Berjaoui - Technological research institute Saint Exupéry, France visibility
IS AI in pathology: from bias mitigation to models interpretability interpreter_mode Camille FRANCHET - Oncopole Claudius Regaud, France
SC Dynamical modelling of gene regulatory networks in Chronic Lymphocytic Leukaemia: Understanding the role of immune cell interactions in cancer cell phenotypes interpreter_mode Malvina MARKU - INSERM, Cancer Research Center of Toulouse, France visibility
IS Complex and simple Al/ML models for harnessing molecular data in oncology interpreter_mode Andrei Zinovyev - EVOTEC, France visibility

16:15 - 17:15 |Coffee break and poster session 1

18:30 - 20:30 |Ice breaking event

08:00 - 08:30 |Welcome coffee

08:30 - 12:10 |Session 2: Microenvironment and resistance

Christine BEZOMBES - Centre de Recherches en Cancérologie de Toulouse-Inserm u1037, France

Catherine MULLER - CNRS IPBS, France

Christine JEAN - CRCT, UMR1037, Inserm, France

IS The extracellular matrix: from proteomic exploration to matritherapies interpreter_mode Alexandra NABA - Department of Physiology and Biophysics, University of Illinois, United States visibility
SC Tumour-stroma interactions in pancreatic cancer metastasis: Mechanisms and therapeutic opportunities interpreter_mode Ainhoa MIELGO - University of Liverpool, United Kingdom visibility
IS Tumor-associated myeloid cells: Harnessing integrins to disrupt their contribution to cancer progression interpreter_mode Frédéric Lagarrigue - Institute of Pharmacology and Structural Biology, France visibility
IS Harnessing gut immunity to target metastases interpreter_mode Christel Devaud - CRCT, France visibility
SC Fibrinogen-like protein 2 (FGL2) is a multifaceted immune checkpoint with potential therapeutic application in B-cell non-Hodgkin Lymphomas interpreter_mode Juan Garcia VALERO - Fundació de Recerca Clínic Barcelona (FCRB)-IDIBAPS, Spain - Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Spain visibility
IS High endothelial venules (HEVs) : specialized blood vessels for lymphocyte entry in tumors during cancer immunotherapy interpreter_mode Jean-Philippe Girard - IPBS-CNRS, Université de Toulouse, France visibility
IS Neural Switch in Pancreatic Cancer: From Early Defense to Tumor Support interpreter_mode Fanny Mann - IBDM UMR7288, France visibility

09:45 - 10:45 |Coffee break and poster session 2

12:10 - 13:00 |Companies and technologies pitches

14:30 - 17:25 |Session 3: Cancer therapeutic innovations

Pierre CORDELIER - CRCT, France

Julie GUILLERMET-GUIBERT - CRCT, France

Julien MAZIERES - CHU de TOULOUSE, Service De Pneumologie INSERM CRCT UMR1037, France

IS Glutamine sensing in pancreatic cancer: from mechanisms of action to therapeutic perspectives interpreter_mode Myriam Martini - Molecular Biotechnology Center, Italy visibility
SC Furin silencing in T cells and repression by small molecule inhibitors reverses the exhausted phenotype of tumor-infiltrating T cells and enhances anti-tumor immunity interpreter_mode Majid KHATIB - INSERM U1312, France visibility
IS Oxaliplatin, ATR inhibitor and anti-PD1 combinaison leads to colon cancer eradication through immune system activation interpreter_mode Céline Gongora - IRCM INSERM U1194, France visibility
IS Deciphering non-genetic tumor adaptation to prevent resistance to targeted therapies in oncogene-addicted lung cancer
SC Ptch1 drug efflux inhibition: a promising strategy to overcome chemotherapy resistance of cancer cells interpreter_mode Isabelle MUS-VETEAU - Institut de Pharmacologie Moléculaire et Cellulaire, CNRS UMR7275, France - Université Côte d'Azur, France visibility
IS From PARP to targeting MTHFD1/2 for cancer specific folate trapping interpreter_mode Thomas Helleday - Science for Life Laboratory, Department of Oncology-Pathology, Sweden visibility
IS Challenges in oncology: the Gustave Roussy perspective interpreter_mode Fabrice BARLESI - Gustave Roussy, France

15:45 - 16:15 |Coffee break and poster session 3

20:30 - 23:59 |Gala dinner

08:00 - 08:30 |Welcome coffee

08:30 - 12:10 |Session 4 : Molecular mechanisms of resistance

Kerstin BYSTRICKY

Didier TROUCHE - Centre de Biologie INtégrative, France

IS Defining mechanisms of genomic evolution in cancer interpreter_mode Sarah McClelland - Barts Cancer Institute, United Kingdom visibility
SC Advanced microscopy methods for the study of breast cancer interpreter_mode Lorenzo SCIPIONI - Centre de Recherche en Cancerologie de Toulouse, France visibility
IS Biomolecular condensates in nuclear organization interpreter_mode Fabian Erdel - Center for Integrative Biology, France visibility
IS Impact of Arginine Citrullination on Transcriptional Control in Cancer interpreter_mode Priyanka SHARMA - Institute of Pharmacology and Structural Biology, France visibility
SC Impact of 5-Fluorouracil on cell plasticity interpreter_mode Laura JENTSCHEL - Institut Génomique Fonctionnelle, France visibility
IS Chromosome and chromatin dynamics during Transcription-coupled DSB repair interpreter_mode Gaëlle Legube - CBI, France visibility
IS Clonal Hematopoiesis in Cancer interpreter_mode Elsa BERNARD - Gustave Roussy Institute, France

10:15 - 10:35 |Coffee break and poster session 4

12:10 - 12:50 |Histone variants and their partners shaping chromatin and cell fate.

Genevieve ALMOUZNI PETTINOTTI - Institut Curie, France

PCO agency - partner of the event :

INSIGHT OUTSIDE

contact@toulouse-onco-week.org
http://www.insight-outside.fr

Project holder :

GIP IUCT
1 Av. Irène Joliot-Curie
31100 Toulouse

http://www.iuct.fr

(*) Prices starting from fixed line incumbent, a surcharge may be applied by operators, counting the second after the first 45 seconds.

According to France's Personal Data Privacy Act in effect since June 2004, you may send a request in writing to INSIGHT OUTSIDE 26 Avenue Jean Kuntzmann 38330 Montbonnot-Saint-Martin / France, or by email webmaster@insight-outside.fr to access your file in order to consult, modify and/or delete your personal information.

© 2005 - 2024 Insight Outside

Organisation congrès scientifique Toulouse